The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Open accessAbstract
BACKGROUND AND AIM Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in patients with cirrhosis and portal pressure (assessed by the hepatic venous pressure gradient [HVPG]) ≥12 mmHg. We aimed to confirm these results in a randomized, placebo-controlled, double blind study. METHODS Multicenter study including 263 patients with cirrhosis due to non-alcoholic steatohepatitis (NASH) and baseline HVPG ≥12 mmHg randomized 1:1:1:1 to emricasan 5 (n=65), 25 (n=65), 50 (n=66) mg or placebo (n=67) orally twice daily for up to 48 weeks. Primary endpoint was change in HVPG (ΔHVPG) at week 24. Secondary endpoints were changes in biomarkers (aminotransferases, caspases, cytokeratins) and development of liver-related outcomes. RESULTS There were no significant differences in ΔHVPG for any emricasan dose vs. placebo (-0.21, -0.45, -0.58 mmHg, respectively) adjusted by baseline HVPG, compensation status, and non-selective beta-blocker use. Compensated subjects (n=201 [76%]) tended to have a greater decrease in HVPG (emricasan all vs. placebo, p=0.06), the decrease being greater in those with higher baseline HVPG (p=0.018), with a significant interaction between baseline HVPG (continuous, p=0.024; dichotomous at 16 mmHg [median], p=0.013) and treatment. Biomarkers decreased significantly with emricasan at week 24 but returned to baseline levels by week 48. New or worsening decompensating events (∼10% over median exposure of 337 days), progression in MELD and Child Pugh scores, and treatment-emergent adverse events were similar among treatment groups. CONCLUSIONS Despite reduction in biomarkers indicating target engagement, emricasan was not associated with improvement in HVPG or clinical outcomes in patients with NASH cirrhosis and severe portal hypertension. Compensated subjects with higher baseline HVPG had evidence of a small treatment effect. Emricasan treatment appeared safe and well-tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390
Self-citationHarrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384
Self-citation
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00674-x · Cited by 382
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
Metadata
- Authors
- Garcia-Tsao, G., Bosch, J., Kayali, Z., Harrison, S. A., Abdelmalek, M. F., Lawitz, E., Satapathy, S. K., Ghabril, M., Shiffman, M. L., Younes, Z. H., Thuluvath, P. J., Berzigotti, A., Albillos, A., Robinson, J. M., Hagerty, D. T., Chan, J. L., Sanyal, A. J., Abdelmalek, M., Bhamidimarri, K., Borg, B., Caldwell, S., Fenkel, J., Freilich, B., Fuchs, M., Ghabril, M., Ghalib, R., Gonzalez, S., Gordon, S., Hameed, B., Harrison, S., Kayali, Z., Kemmer, N., Korenblat, K., Lai, M., Landis, C., Lawitz, E., Lee, W., Lidofsky, S., Mena, E., Noureddin, M., Paredes, A., Pyrsopoulos, N., Reddy, R., Rinella, M., Rockey, D., Rodriguez, M., Ryan, M., Sarkar, S., Satapathy, S., Scanga, A., Shiffman, M., Siddiqui, M., Simonetto, D., Syn, W., Thuluvath, P., Vemulapalli, R., Vierling, J., Younes, Z., Albillos, A., Ruiz-Tapiador, J. A., Augustin, S., Calleja, J., Garcia, J. C., Buey, L. G., Garcia-Pagan, J. C., Villanueva, C., Bureau, C., Carbonell, N., Leroy, V., Rautou, P.-E., Heinzow, H., Schiefke, I., Zipprich, A., Berzigotti, A., & Muellhaupt, B.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 72
- Issue
- 5
- Pages
- 885-895
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2995314841
- Cited by
- 158
- References
- 2
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. https://app.cochat.ai/papers/10.1016/j.jhep.2019.12.010
- The paper
- Garcia-Tsao, G., Bosch, J., Kayali, Z., Harrison, S. A., Abdelmalek, M. F., Lawitz, E., Satapathy, S. K., Ghabril, M., Shiffman, M. L., Younes, Z. H., Thuluvath, P. J., Berzigotti, A., Albillos, A., Robinson, J. M., Hagerty, D. T., Chan, J. L., Sanyal, A. J., Abdelmalek, M., Bhamidimarri, K., . . . Muellhaupt, B. (2020). Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.12.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.